Watchlist Price Alert

Taysha Gene Therapies Inc... (TSHA)

NASDAQ: TSHA · Real-Time Price · USD

2.79

0.08 (2.95%)

At close: Jun 02, 2025, 3:59 PM

2.79

0.18%

After-hours: Jun 02, 2025, 07:49 PM EDT

2.95% (1D)

Bid	2.66
Market Cap	597.83M
Revenue (ttm)	7.22M
Net Income (ttm)	-86.77M
EPS (ttm)	-0.34
PE Ratio (ttm)	-8.19
Forward PE	-6.95
Analyst	Buy

Ask	2.8
Volume	3,050,403
Avg. Volume (20D)	3,198,660
Open	2.73
Previous Close	2.71
Day's Range	2.65 - 2.81
52-Week Range	1.05 - 4.32
Beta	0.88

About TSHA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TSHA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TSHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

5 days ago

+12.7%

Taysha Gene Therapies shares are trading higher af... Unlock content with Pro Subscription

4 days ago

-6.51%

Taysha Gene Therapies shares are trading higher. The company announced a proposed public offering of common stock.

News

5 days ago · seekingalpha.com

Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP Amendments

Taysha Gene Therapies, Inc. achieved positive updated data from Part A of the phase 1/2 REVEAL study using TSHA-102 to treat patients with Rett Syndrome. Alignment gained with FDA on IND amendments to...

5 days ago · benzinga.com

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

Taysha Gene Therapies Inc. TSHA on Wednesday announced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the U.S. Food and Drug Administration (FDA).

2 weeks ago · seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Hayleigh Collins - Senior Director, Corporate Communications and Investor Relat...

2 weeks ago · zacks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.

4 weeks ago · zacks.com

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · nypost.com

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...